AAPL 182.74 0.1864% MSFT 410.54 0.2932% GOOG 171.16 -1.0521% GOOGL 169.38 -1.092% AMZN 188.0 -0.4026% NVDA 904.12 -0.1568% META 472.6 0.9311% TSLA 174.72 -1.7378% TSM 143.6 1.7646% LLY 775.0 -0.3561% V 277.19 0.2641% AVGO 1325.37 1.7082% JPM 195.65 2.0339% UNH 503.21 0.4491% NVO 126.69 -0.4714% WMT 60.3 -0.5279% LVMUY 169.84 -0.2174% XOM 116.15 -0.0172% LVMHF 846.814 -0.7252% MA 454.77 0.3774%
Last update at 2024-05-08T20:06:00Z
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 3591.80M | 1745.20M | 5047.50M | 7125.90M | 5899.60M |
Minority interest | 85.30M | 171.50M | 59.90M | -4.10000M | 43.30M |
Net income | 3046.90M | 1556.10M | 4000.60M | 5888.50M | 4430.70M |
Selling general administrative | 2403.60M | 2623.60M | 2504.00M | 2374.70M | 2106.30M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 7895.10M | 8872.00M | 11639.40M | 12422.50M | 11636.60M |
Reconciled depreciation | 365.90M | 487.70M | 457.20M | 680.60M | 1016.60M |
Ebit | 2320.20M | 2840.70M | 4550.10M | 7042.60M | 6113.00M |
Ebitda | 2686.10M | 3656.60M | 4807.30M | 7518.70M | 6860.30M |
Depreciation and amortization | 365.90M | 815.90M | 257.20M | 476.10M | 747.30M |
Non operating income net other | 614.50M | -1060.60000M | 502.70M | 3.90M | 11.00M |
Operating income | 2320.20M | 2840.70M | 4550.10M | 7042.60M | 5888.60M |
Other operating expenses | 7271.50M | 8173.70M | 8998.30M | 7342.20M | 7452.10M |
Interest expense | 246.60M | 253.60M | 222.50M | 187.40M | 200.60M |
Tax provision | 632.80M | 52.50M | 992.30M | 1158.00M | 1425.60M |
Interest income | 89.30M | 11.00M | 42.00M | 120.00M | 112.50M |
Net interest income | -157.30000M | -242.60000M | -180.50000M | -67.40000M | -88.10000M |
Extraordinary items | - | - | - | - | -23.70000M |
Non recurring | 131.10M | 18.00M | 75.00M | 1.50M | 124.50M |
Other items | - | - | - | - | - |
Income tax expense | 632.80M | 52.50M | 992.30M | 1158.00M | 1425.60M |
Total revenue | 10173.40M | 10981.70M | 13444.60M | 14377.90M | 13452.90M |
Total operating expenses | 4993.20M | 6064.00M | 7193.10M | 5386.80M | 5635.80M |
Cost of revenue | 2278.30M | 2109.70M | 1805.20M | 1955.40M | 1816.30M |
Total other income expense net | 1271.60M | -1095.50000M | 497.40M | 83.30M | -101.20000M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 2961.60M | 1692.70M | 4055.20M | 5967.90M | 4474.00M |
Net income applicable to common shares | 3046.90M | 1556.10M | 4000.60M | 5888.50M | 4430.70M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 24554.10M | 23877.30M | 24618.90M | 27234.30M | 25288.90M |
Intangible assets | 1850.10M | 2221.30M | 3084.30M | 3527.40M | 3120.00M |
Earning assets | - | - | - | - | - |
Other current assets | 1417.60M | 1153.10M | 1294.60M | 1221.20M | 1214.50M |
Total liab | 11165.70M | 12917.60M | 13932.80M | 13895.20M | 12257.30M |
Total stockholder equity | 13388.40M | 10959.70M | 10686.10M | 13339.10M | 13031.60M |
Deferred long term liab | 334.70M | 694.50M | 1032.80M | 2810.80M | 1636.20M |
Other current liab | 2781.30M | 3299.10M | 3287.30M | 3368.00M | 2924.70M |
Common stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
Capital stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
Retained earnings | 16466.50M | 13911.70M | 13976.30M | 16455.40M | 16257.00M |
Other liab | 1278.90M | 2015.00M | 2362.40M | 4159.70M | 3025.60M |
Good will | 5749.00M | 5761.10M | 5762.10M | 5757.80M | 5706.40M |
Other assets | 1652.90M | 3354.60M | 4196.00M | 3232.10M | 2160.50M |
Cash | 3419.30M | 2261.40M | 1331.20M | 2913.70M | 1224.60M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 3272.80M | 4298.20M | 3742.20M | 4863.80M | 3295.20M |
Current deferred revenue | - | -589.20000M | - | -530.80000M | - |
Net debt | 3194.70M | 5342.10M | 6497.00M | 3453.80M | 4711.90M |
Short term debt | - | 999.10M | 7426.00M | 1495.80M | - |
Short long term debt | - | 999.10M | - | 1495.80M | - |
Short long term debt total | 6614.00M | 7603.50M | 7828.20M | 6367.50M | 5936.50M |
Other stockholder equity | -2913.30000M | -2845.40000M | -2991.30000M | -2981.20000M | -2985.10000M |
Property plant equipment | 3298.60M | 3416.40M | 3411.50M | 3247.30M | 3601.20M |
Total current assets | 9791.20M | 7856.50M | 6887.10M | 8381.80M | 7640.90M |
Long term investments | 2234.90M | 892.00M | 772.10M | 1408.10M | 1375.90M |
Net tangible assets | 5798.80M | 2913.80M | 1853.90M | 4058.00M | 4213.20M |
Short term investments | 1473.50M | 1541.10M | 1278.90M | 1562.20M | 2313.40M |
Net receivables | 2136.40M | 1549.40M | 1913.80M | 1880.50M | 1958.50M |
Long term debt | 6281.00M | 6274.00M | 7426.20M | 4459.00M | 5936.50M |
Inventory | 1344.40M | 1351.50M | 1068.60M | 804.20M | 929.90M |
Accounts payable | 491.50M | 589.20M | 454.90M | 530.80M | 370.50M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | -9.50000M | 63.50M | -14.20000M | -4.10000M | -8.00000M |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -164.90000M | -106.70000M | -299.00000M | -135.20000M | -240.40000M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | 16466.50M | 13911.70M | 13976.30M | 16455.40M | 16257.00M |
Treasury stock | -2977.10000M | -2977.10000M | -2977.10000M | -2977.10000M | -2977.10000M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 1529.20M | 1941.00M | -1369.50000M | -3232.10000M | -2153.90000M |
Deferred long term asset charges | - | - | - | 3232.10M | 2153.90M |
Non current assets total | 14762.90M | 16020.80M | 17731.80M | 18852.50M | 17648.00M |
Capital lease obligations | 333.00M | 330.40M | 402.00M | 412.70M | - |
Long term debt total | 6281.00M | 6274.00M | 7426.20M | 4459.00M | 5936.50M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | 1576.60M | -309.80000M | -29.90000M | 1233.70M | 339.40M |
Change to liabilities | -347.70000M | -9.10000M | -50.40000M | 213.00M | 770.90M |
Total cashflows from investing activities | 1576.60M | -563.70000M | -608.60000M | 470.50M | -2046.30000M |
Net borrowings | -1002.20000M | -170.00000M | 1467.40M | 1467.40M | -3.20000M |
Total cash from financing activities | -1747.30000M | -2086.20000M | -5272.70000M | -5860.40000M | -4472.00000M |
Change to operating activities | -224.40000M | -238.70000M | 193.80M | 133.60M | 335.80M |
Net income | 2961.60M | 1727.60M | 4060.50M | 5888.50M | 4474.00M |
Change in cash | 1157.90M | 930.20M | -1582.50000M | 1689.10M | -349.20000M |
Begin period cash flow | 2261.40M | 1331.20M | 2913.70M | 1224.60M | 1573.80M |
End period cash flow | 3419.30M | 2261.40M | 1331.20M | 2913.70M | 1224.60M |
Total cash from operating activities | 1384.30M | 3639.90M | 4229.80M | 7078.60M | 6187.70M |
Issuance of capital stock | - | - | - | - | - |
Depreciation | 518.40M | 487.70M | 457.20M | 680.60M | 1016.60M |
Other cashflows from investing activities | 604.10M | 4.20M | -153.90000M | -248.70000M | -1615.10000M |
Dividends paid | - | 0.70M | 4.60M | - | 36.40M |
Change to inventory | -320.20000M | -462.40000M | -316.30000M | -19.20000M | -52.10000M |
Change to account receivables | -203.40000M | 324.80M | 2.80M | 68.80M | -205.20000M |
Sale purchase of stock | -750.00000M | -1800.00000M | -6679.10000M | -5868.30000M | -4352.60000M |
Other cashflows from financing activities | 6.80M | -114.80000M | 2915.60M | 7.90M | -114.10000M |
Change to netincome | -1471.30000M | 743.30M | 673.60M | 254.90M | 296.90M |
Capital expenditures | 243.20M | 294.90M | 551.80M | 669.50M | 886.10M |
Change receivables | -203.40000M | 324.80M | 2.80M | 68.80M | -205.20000M |
Cash flows other operating | 246.90M | 828.00M | -597.60000M | -8.00000M | -113.40000M |
Exchange rate changes | - | - | - | 0.40M | -18.60000M |
Cash and cash equivalents changes | 1213.60M | 990.00M | -1651.50000M | 1689.10M | -349.20000M |
Change in working capital | -890.30000M | -145.50000M | -187.20000M | 199.30M | 400.20M |
Stock based compensation | 254.10M | 238.60M | 198.30M | 182.30M | 157.50M |
Other non cash items | -1290.90000M | 1758.30M | -448.00000M | 60.80M | 31.10M |
Free cash flow | 1141.10M | 3345.00M | 3678.00M | 6409.10M | 5301.60M |
Sector: Healthcare Industry: Drug Manufacturers - General
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
BIIB Biogen Inc |
0.80 0.37% | 219.72 | 25.64 | 15.13 | 3.60 | 2.48 | 4.14 | 17.90 |
LLY Eli Lilly and Company |
-2.77 0.36% | 775.00 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
JNJ Johnson & Johnson |
0.23 0.15% | 148.95 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
ABBV AbbVie Inc |
-2.1 1.29% | 160.45 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
MRK Merck & Company Inc |
-0.83 0.64% | 129.55 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
225 Binney Street, Cambridge, MA, United States, 02142
Name | Title | Year Born |
---|---|---|
Mr. Michael R. McDonnell CPA | Exec. VP & CFO | 1964 |
Ms. Susan H. Alexander Esq. | Exec. VP, Chief Legal Officer & Sec. | 1957 |
Mr. Christopher A. Viehbacher | Pres, CEO & Director | 1960 |
Ms. Robin C. Kramer | Sr. VP & Chief Accounting Officer | 1966 |
Ms. Nicole Murphy | Head of Pharmaceutical Operations & Technology | NA |
Mr. Michael Hencke | Head of Investor Relations | NA |
Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corp. Affairs | NA |
Dr. Ginger Gregory | Exec. VP & Chief HR Officer | 1968 |
Dr. Anabella Villalobos Ph.D. | Head of Biotherapeutics & Medicinal Sciences | 1959 |
Dr. Sanjay Jariwala | Sr. VP of Worldwide Medical | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).